We believe in a world

where everyone has access to the health care they need to thrive, and where governments and public health organizations around the world have the tools they need to address large-scale infectious disease scenarios head-on.


Domus Diagnostics seeks to create tests for infectious diseases that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises.


The Problem


  • At its lowest point, COVID-19 is still newly infecting over 11 million people worldwide each week (Disaster Philanthropy, March 2022). The virus continues to mutate, with more contagious or vaccine-resistant variants potentially still to emerge. 

  • Influenza, RSV, and other respiratory diseases continue to claim 300,000 to 700,000 lives per year (CDC, March 2022)



  • As new infectious disease outbreaks emerge with increasing frequency, reliable surveillance testing will be needed to prevent them from reaching COVID-19-levels of global impact

  • Global population-scale surveillance tests will need to be tailored to daily home-use / point-of-care tests (schools, airports, employers, etc.)


The Solution

A simple, affordable, accurate, and rapid at-home nucleic acid test

Performance Matters

Nucleic Acid Testing (NAT) technologies required to curb outbreaks of endemic SARS-Cov-2

To prevent community spread of infectious respiratory diseases like COVID-19, pre-symptomatic and asymptomatic cases need to be identified and contained as early as possible, which can only be achieved with NAT (PCR, RTLAMP) technologies, not with rapid antigen tests.

Detection Performance of Test Methods over Time (days)


Domus Diagnostics is powered by a world class team, 

who have invented the cutting-edge technology required to meet these performance requirements at a fraction of the cost.